Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5- dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment

Gopalakrishnan Aridoss, Bo Zhou, David L Lampi Hermanson, Nicholas P. Bleeker, Chengguo Xing

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Multidrug resistance (MDR) against standard therapies poses a serious challenge in cancer treatment, and there is a clinical need for new anticancer agents that would selectively target MDR malignancies. Our previous studies have identified a 4H-chromene system, CXL017 (4) as an example, that can preferentially kill MDR cancer cells. To further improve its potency, we have performed detailed structure-activity relationship (SAR) studies at the 3, 4, and 6 positions of the 4H-chromene system. The results reveal that the 3 and 4 positions prefer rigid and hydrophobic functional groups while the 6 position prefers a meta or para-substituted aryl functional group and the substituent should be small and hydrophilic. We have also identified and characterized nine MDR cancer cells that acquire MDR through different mechanisms and demonstrated the scope of our new lead, 9g, to selectively target different MDR cancers, which holds promise to help manage MDR in cancer treatment.

Original languageEnglish (US)
Pages (from-to)5566-5581
Number of pages16
JournalJournal of medicinal chemistry
Volume55
Issue number11
DOIs
StatePublished - Jun 14 2012

Fingerprint Dive into the research topics of 'Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5- dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment'. Together they form a unique fingerprint.

  • Cite this